Literature DB >> 27215153

Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes.

Tracey C Vlahovic1.   

Abstract

Onychomycosis is the most common nail disease seen in podiatric practice. Effective long-term management remains problematic. We need to treat onychomycosis effectively to prevent its progression into a severe, debilitating, and painful condition, and to manage recurrence. With new agents now available and greater discussion on management strategies, this article reviews the appropriate evaluation of the disease, treatment options, and optimal patient outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Efinaconazole; Laser; Mycosis; Onychomycosis; Tavaborole; Tinea pedis; Toenail; Trichophyton rubrum

Mesh:

Year:  2016        PMID: 27215153     DOI: 10.1016/j.cpm.2016.02.001

Source DB:  PubMed          Journal:  Clin Podiatr Med Surg        ISSN: 0891-8422            Impact factor:   1.231


  12 in total

1.  Iontophoresis application for drug delivery in high resistivity membranes: nails and teeth.

Authors:  Jayanaraian F Martins Andrade; Thamires da Cunha Miranda; Marcílio Cunha-Filho; Stephânia Fleury Taveira; Guilherme M Gelfuso; Taís Gratieri
Journal:  Drug Deliv Transl Res       Date:  2022-10-08       Impact factor: 5.671

Review 2.  Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis.

Authors:  Verónica Velasquez-Agudelo; Jaiberth Antonio Cardona-Arias
Journal:  BMC Infect Dis       Date:  2017-02-22       Impact factor: 3.090

3.  A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis.

Authors:  Anarosa B Sprenger; Katia Sheylla Malta Purim; Flávia Sprenger; Flávio Queiroz-Telles
Journal:  J Fungi (Basel)       Date:  2019-09-04

Review 4.  Recent advances in therapies for onychomycosis and its management.

Authors:  Aditya K Gupta; Nadia Stec
Journal:  F1000Res       Date:  2019-06-25

5.  Recent Patents on Permeation Enhancers for Drug Delivery Through Nails.

Authors:  Tainá Kreutz; Sheila Porto de Matos; Letícia Scherer Koester
Journal:  Recent Pat Drug Deliv Formul       Date:  2019

Review 6.  Onychomycosis: An Updated Review.

Authors:  Alexander K C Leung; Joseph M Lam; Kin F Leong; Kam L Hon; Benjamin Barankin; Amy A M Leung; Alex H C Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2020

7.  Preparation of terpolymer capsules containing Rosmarinus officinalis essential oil and evaluation of its antifungal activity.

Authors:  Juliete Silva Neves; Zita Lopes-da-Silva; Maria de Sousa Brito Neta; Sacha Braun Chaves; Yanna Karla de Medeiros Nóbrega; Angelo Henrique de Lira Machado; Fabricio Machado
Journal:  RSC Adv       Date:  2019-07-22       Impact factor: 3.361

8.  Onychomycosis: Recommendations for Diagnosis, Assessment of Treatment Efficacy, and Specialist Referral. The CONSONANCE Consensus Project.

Authors:  Bianca Maria Piraccini; Michela Starace; Adam I Rubin; Nilton Gioia Di Chiacchio; Matilde Iorizzo; Dimitris Rigopoulos
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-09

9.  Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B-Loaded Nail Lacquer.

Authors:  Aleph M S Souza; Renato C A Ribeiro; Gleyse K L O Pinheiro; Francisco I Pinheiro; Wógenes N Oliveira; Luanda B F C Souza; André L Silva; Lucas Amaral-Machado; Éverton N Alencar; Guilherme M Chaves; Eryvaldo S T Egito
Journal:  Pharmaceutics       Date:  2021-05-24       Impact factor: 6.321

10.  NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.

Authors:  Derry K Mercer; Jennifer C Robertson; Lorna Miller; Colin S Stewart; Deborah A O'Neil
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.